MetaCap

Fate Therapeutics (FATE) vs Innate Pharma S.A. (IPHA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Innate Pharma S.A. (IPHA) over the past year, losing 10.8% versus a loss of 52.6%. Over five years, IPHA leads with a -82.0% price change compared with -98.3% for FATE. Fate Therapeutics is the larger company by market cap ($111.8 million vs $96.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FATE-10.78%IPHA-52.56%
+215%+75%-65%
Nov 21, 20251 yearNov 20, 2026
FATE-98.36%IPHA-82.77%
+21%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FATE versus IPHA key metrics
MetricFATEIPHA
Share price$0.919$0.8634
Market cap$111.82M$96.44M
1-day change-9.01%-8.14%
YTD return-6.22%-50.66%
1-year return-10.78%-52.56%
5-year return-98.25%-82.01%
EPS (TTM)$-1.03$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.65M—
Revenue growth (YoY)-51.24%—
Net income (latest FY)$-136.31M—
Operating margin-2222.45%—
Net margin-2051.08%—
52-week high$3.23$2.71
52-week low$0.90$0.829
Distance from 52-week high-71.55%-68.14%
Analyst consensusbuybuy
Avg. price target upside+522.42%+826.57%
Average volume1.53M42.76K
Shares outstanding121.67M111.70M
Employees161120
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed IPHA by 41.8 percentage points over the past year.

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

About Innate Pharma S.A.

IPHA stock →

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees

FATE vs IPHA FAQ

Which is bigger, Fate Therapeutics or Innate Pharma S.A.?

Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $96.44M for Innate Pharma S.A. (IPHA).

Which stock has performed better over the past year, FATE or IPHA?

FATE returned -10.78% over the past 12 months, compared with -52.56% for IPHA (price return, excluding dividends). Past performance does not predict future results.

Are Fate Therapeutics and Innate Pharma S.A. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons